Phenytoin (Eptoin)

Overview

Phenytoin (Eptoin), also known as Dilantin or Diphenylhydantoin, is a widely used anticonvulsant drug for the control of seizures. It is prescribed for epilepsy, tonic-clonic seizures, psychomotor seizures, partial seizures, and status epilepticus, and is also used to prevent seizures occurring during or after brain or nervous system surgeries.

Phenytoin works by blocking voltage-gated sodium channels in neuronal and cardiac tissue. This action prevents abnormal electrical activity in the brain, particularly in neurons with high-frequency firing, thereby stopping the propagation of seizures.

Despite its effectiveness, phenytoin has a narrow therapeutic index, meaning small changes in dosage can shift levels from therapeutic to toxic. The normal serum concentration is 10–20 µg/mL, while levels above 20 µg/mL indicate toxicity. Its long half-life (average 22 hours) and extensive hepatic metabolism through CYP2C9 and CYP2C19 enzymes further highlight the need for careful monitoring.

Symptoms

Phenytoin therapy offers significant seizure control but may cause symptoms if dosages are inappropriate or toxicity develops:

1. Therapeutic effects:
   1. Optimal seizure prevention and control
   2. Protection during brain surgery
   3. Relief in bipolar disorder, wound healing, and retina protection (off-label uses)
2. Adverse symptoms:
   1. Headache, dizziness, or drowsiness
   2. Nervousness, unsteadiness, or shakiness
   3. Nausea, vomiting, or constipation
   4. Gum swelling (gingival hyperplasia) and sore gums
   5. Excessive hair growth (hirsutism)
   6. Sedation and confusion
   7. Ataxia (loss of coordination) and nystagmus (involuntary eye movements)
   8. Bone softening (osteomalacia) and megaloblastic anemia
   9. Severe hypersensitivity reactions such as Stevens-Johnson syndrome
   10. Teratogenic effects, including fetal hydantoin syndrome if taken during pregnancy
3. Toxicity symptoms:
   1. Ataxia, confusion, coma, and worsening seizures

These symptoms emphasize the importance of therapeutic drug monitoring (TDM).

Causes

The main causes of phenytoin-related complications include:

1. Incorrect Dosage: Overdose beyond the 20 µg/mL threshold can lead to toxicity.
2. Drug Interactions: Phenytoin induces CYP3A4 enzymes, affecting drugs like oral contraceptives, anticoagulants, cyclosporine, and theophylline.
3. Hepatic Metabolism: Impaired liver function reduces clearance, raising serum levels.
4. Renal Impairment: Alters protein binding and increases free drug concentration.
5. Pregnancy and Age: Phenytoin pharmacokinetics are altered in pregnant women, infants, and elderly patients.
6. IV Administration Issues: Rapid infusion exceeding 50 mg/min or mixing with dextrose may cause crystal formation and cardiac risks.

Risk Factors

Certain groups are more prone to phenytoin-related risks:

1. Epileptic Patients: Long-term users need careful dose monitoring.
2. Liver Disease Patients: Reduced metabolism raises serum concentration.
3. Renal Disease Patients: Higher risk of altered protein binding and toxicity.
4. Pregnant Women: Phenytoin is teratogenic, increasing risks for congenital anomalies.
5. Polypharmacy Patients: Those on anticoagulants, immunosuppressants, or hormonal therapies face interaction risks.
6. Patients with Heart Conditions: Those with sinus bradycardia, atrioventricular block, or preexisting cardiac disorders.
7. Children and Elderly: Increased sensitivity to adverse effects.
8. Patients with Drug Hypersensitivity: At risk of reactions like Stevens-Johnson syndrome or drug-induced gum disease.

These risk groups require individualized monitoring for safe therapy.

Prevention

Preventing complications with phenytoin involves proper monitoring, safe prescribing, and patient education:

1. Therapeutic Drug Monitoring: Keep serum levels between 10–20 µg/mL; subtherapeutic levels may cause breakthrough seizures, while excess causes toxicity.
2. Safe Administration: Administer orally when possible; for IV use, dilute with sodium chloride, avoid dextrose, and infuse slowly (<50 mg/min).
3. Drug Interaction Awareness: Monitor patients on interacting drugs like warfarin, contraceptives, and cyclosporine.
4. Patient Counseling: Educate patients about gum care to prevent gingival hyperplasia, and advise them to avoid alcohol and self-medication.
5. Special Populations: Adjust doses for children, elderly, pregnant women, and those with liver/kidney issues.
6. Sample Handling: For serum level testing, collect blood in plain tubes, separate serum promptly, and store at 2–8°C with ice packs during transport.
7. Gradual Dose Adjustments: Prevent withdrawal seizures by avoiding abrupt discontinuation.

By following these measures, clinicians can reduce phenytoin-related risks while ensuring effective seizure control.